Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen, LJ Lin - Thrombosis research, 2014 - Elsevier
Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
[引用][C] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen, LJ Lin - Thrombosis Research, 2014 - cir.nii.ac.jp
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism
in atrial fibrillation in Taiwan | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
in atrial fibrillation in Taiwan | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen… - Thrombosis …, 2014 - researchoutput.ncku.edu.tw
Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen, LJ Lin - Thrombosis Research, 2014 - infona.pl
Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done mostly in
Western countries. It remains to be seen whether dabigatran will be cost effective in a …
Western countries. It remains to be seen whether dabigatran will be cost effective in a …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen… - Thrombosis …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
CH Chang, YHK Yang, JH Chen… - Thrombosis …, 2014 - thrombosisresearch.com
Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
CH Chang, YH Yang, JH Chen, LJ Lin - Thrombosis Research, 2014 - europepmc.org
Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …